BMI View: Myanmar's plan to introduce a maximum retail price for pharmaceuticals will not be fully
implemented. The country's Food and Drug Administration lacks the regulatory capacity to enforce such a
scheme as it struggles to address existing challenges such as the ..."
BMI View: Significant regulatory changes in response to the illegal rebate scandal in South Korea will be
unlikely. The country already has tough laws in place, which can be leveraged to impose tough penalties on
Novartis and other firms practicing such sales tactics. ..."
BMI View: Bangladesh's pharmaceutical export trajectory will be positive. Due to the tough competitive
domestic environment, local drugmakers have expanded successfully into frontier and emerging markets in
pursuit of commercial opportunities. With this as a foundat ..."
BMI View: Israel will continue to be targeted by multinational drugmakers as a destination for innovative
drug sales; however, their relative success will be limited by funding constraints towards the country's
health services basket and the lack of transparency wit ..."
BMI View: There will be broad healthcare policy continuity in the Philippines under President Rodrigo
Duterte. In contrast to his other more controversial positions, Duterte's statements on healthcare are
relatively more nuanced and in line with current policy direc ..."
BMI View: The UAE will remain one of the most attractive pharmaceutical and healthcare markets in the
Middle East and Africa Region. A rising chronic disease burden will drive demand for high-value
medicines, particularly cancer drugs. The market is dominated by pat ..."
BMI View: The removal of economic sanctions heralds an era of uncertainty for Iran's pharmaceutical
market. Underlying issues regarding the operating environment will prevent an immediate uptick in
multinational drugmaker interest; rather, this will be a gradual proce ..."
BMI View: Iraq's ailing domestic landscape will dampen investor confidence in the country's
pharmaceuticals and healthcare sectors over at least the next few years if not longer. Although the
government remains committed to healthcare provision, economic and security ..."
BMI View: The Oman Ministry of Health's decision to postpone the latest phase of medicine price
reductions highlights the opaque nature of the country's pharmaceutical sector. Over the long term, Oman's
population will benefit from more affordable healthcare services ..."
BMI View: Pakistan's pharmaceutical market will remain a low priority for innovative drugmakers.
Downward price pressures on pharmaceutical prices coupled with uncertainty surrounding the country's
policy direction impinge on potential commercial opportunities, while ..."